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Abstract It is believed that senescent cells contribute to
the progression of primary and metastatic tumors, how-
ever, the exact mechanisms of this activity remain elu-
sive. In this report we show that senescent human
peritoneal mesothelial cells (HPMCs) alter the secretory
profile of ovarian cancer cells (A2780, OVCAR-3,
SKOV-3) by increasing the release of four angiogenic
agents: CXCL1, CXCL8, HGF, and VEGF. Proliferation
and migration of endothelial cells subjected to condi-
tioned medium generated by: cancer cells modified by
senescent HPMCs; cancer cells co-cultured with senescent
HPMCs; and by early-passage HPMCs from aged donors,
were markedly intensified. The same was the case for the
vascularization, size and number of tumors that developed
in the mouse peritoneum upon injection of ovarian cancer
cells with senescent HPMCs. When the identified pro-
angiogenic proteins were neutralized in conditioned
medium from the cancer cells, both aspects of endothelial
cell behavior intensified in vitro in response to senescent
HPMCs were markedly reduced. The search for mediators
of senescent HPMC activity using specific neutralizing
antibodies and recombinant exogenous proteins showed
that the intensified angiogenic potential of cancer cells
was elicited by IL-6 and TGF-b1. At the transcriptional
level, increased proliferation and migration of endothelial
cells exposed to cancer cells modified by senescent
HPMCs was regulated by HIF-1a, NF-jB/p50 and AP-1/
c-Jun. Collectively, our findings indicate that senescent
HPMCs may promote the progression of ovarian cancer
cells by reprogramming their secretory phenotype towards
increased production of pro-angiogenic agents and sub-
sequent increase in the angiogenic capabilities of the
vascular endothelium.
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Introduction
There is general agreement that senescent cells which
accumulate in tissues during aging actively contribute to
the development of a permissive tissue microenvironment
in which pre-malignant and malignant cells acquire a more
aggressive phenotype [1]. This property of senescent cells
stems from their ability to secrete increased amounts of
agents that disrupt normal tissue architecture, thus creating
inflammation-like conditions and facilitating all critical
aspects of cancer progression [2].
One of the most lethal age-associated malignancies is
ovarian cancer [3]. In the late stages of the disease, cancer
cells disseminate by ovarian surface shedding and colonize
the peritoneal cavity. It has been found that the intraperi-
toneal spread of this malignancy is controlled by interac-
tions between cancer cells and normal human peritoneal
mesothelial cells (HPMCs) [4]. One of the most important
elements of these interactions is the HPMCs’ ability to
secrete various pro-angiogenic stimuli that contribute to the
development of a niche in which cancer cells preferentially
form tumors [5, 6]. Interestingly, the magnitude of pro-
angiogenic agent release by the HPMCs has been found to
be markedly increased when the cells become senescent
[7]. Taking into account the fact that senescent HPMCs
accumulate in the omentum during aging [8], these cells’
pro-angiogenic phenotype may have special importance in
the increased aggressiveness of ovarian malignancy in
elderly patients.
In this report we again focused on the pro-angiogenic
capabilities of senescent HPMCs and we examined our
original hypothesis which stated that these cells may sup-
port the expansion of ovarian cancer cells by altering their
secretory profile towards increased production of autolo-
gous angiogenic agents. To this end, ovarian cancer cells
were subjected to conditioned medium (CM) from young
and senescent HPMCs, then the secretion of several soluble
mediators of angiogenesis by these cells was analyzed. In
order to check whether the altered cancer cell secretome is
biologically relevant, CM obtained from: (i) cancer cells
modified by young/senescent HPMCs; (ii) cancer cells co-
cultured with young/senescent HPMCs; and (iii) cancer
cells subjected to CM generated by young HPMCs derived
from donors of varying ages, was applicated to primary
endothelial cells to determine the efficacy of their prolif-
eration and migration. In addition, the vascularization, size
and number of tumors that developed in the mouse peri-
toneum upon injection of the cancer cells together with
young or senescent HPMCs were examined. The phe-
nomenological investigations were followed by mechanis-
tic studies in which (a) senescent HPMC-derived
mediator(s) of altered cancer cell secretory properties as
well as signaling pathways activated in the cancer cells in
response to these stimuli were identified.
Materials and methods
Chemicals
Unless otherwise stated, all chemicals were purchased from
Sigma (St. Louis, MO). Cell culture plastics were from Nunc
(Roskilde, Denmark). Recombinant human IL-6 and TGF-b1
were from R&D Systems (Abingdon, UK). Neutralizing
antibodies as well as appropriate isotype-matched control
antibodies were from R&D Systems and Abcam (Cambridge,
UK). Bay 87-2243, MG-132 and 3-aminobenzamide (3-AB)
were from Bayer Pharma AG (Wuppertal, Germany), Biomol
(Plymouth Meeting, PA) and Sigma, respectively.
Cell cultures
Human peritoneal mesothelial cells (HPMCs) were isolated
from pieces of omentum, as described elsewhere [9]. The
tissues were obtained from 22 patients undergoing elective
abdominal surgery. The reasons for the surgery included:
aortic aneurysm (12), hernia (5), bowel obstruction (3), and
cholelithiasis (2). All cultures were established from indi-
viduals with no evidence of peritonitis, diabetes, uremia or
peritoneal malignancy. The age of the donors ranged from
19 to 85 years old. Cells were identified as pure mesothe-
lial by their typical cobblestone appearance at confluence
and uniform positive staining for HBME-1 and Wt-1
antigens. The study was approved by an institutional ethics
committee and was performed in accordance with the
ethical standards as laid down in the 1964 Declaration of
Helsinki. HPMCs were propagated in M199 medium with
10 % fetal bovine serum (FBS).
Senescence of HPMCs was induced by serial passaging
until their ability to replicate was exhausted. Cells were
considered senescent when they developed a hypertrophic
morphology and failed to increase in number for 4 weeks
[10]. Cells described as ‘‘young’’ were derived from the
first passage. In all in vitro and in vivo experiments, young
and senescent cells obtained exclusively from the same
donors were compared.
Ovarian cancer cells A2780 and SKOV-3 were pur-
chased from the ECCC (Porton Down, UK) and maintained
in RPMI 1640 medium with L-glutamine (2 mmol/L),
penicillin (100 U/ml), streptomycin (100 g/ml) and 10 %
FBS. The OVCAR-3 line was obtained from the ATCC
(Rockville, MD) and grown in RPMI 1640 with L-glu-
tamine (2 mmol/L), HEPES (10 mmol/L), glucose
(4500 mg/L), insulin (0.01 mg/ml), and 20 % FBS.
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Human umbilical vein endothelial cells (HUVECs) were
purchased in the ATCC. The cells were cultured in DMEM
with 15 % FBS, L-glutamine (2 mM), HEPES (20 mM),
EGF (10 lg/ml), heparin (5 U/ml), penicillin (100 U/ml),
and streptomycin (100 lg/ml).
Conditioned media
In order to generate conditioned medium (CM), young and
senescent HPMCs were seeded into 25 cm5 flasks, allowed
to attach for 4 h, and were incubated in serum-free medium
for 72 h. The ovarian cancer cells were grown until
reaching 80–90 % confluency and then were maintained in
serum-free conditions for 24 h. Afterwards, the cells were
incubated with CM produced by young/senescent HPMCs
and with CM generated by intact cancer cells for the next
24 h. After incubation the media were removed, the cells
were washed and then subjected to serum-free medium (for
24 h) to generate autologous CM. In some experiments the
CM was also generated by cancer cells co-cultured with
young or senescent HPMCs in an arbitrarily selected 1:1
ratio for 72 h. All conditioned media that were obtained
were filtered and frozen at -80 C until required.
Examination of cell secretome
Concentrations of soluble agents in cell culture super-
natants from young and senescent HPMCs and from
ovarian cancer cells were measured with appropriate
DuoSet Immunoassay Development kits (R&D Systems)
according to the manufacturer’s instructions.
Proliferation and migration assays
Endothelial cell proliferation was assessed in serum-free
conditions on low-density cultures by using the radioiso-
tope method [10]. Endothelial cell migration towards CM
obtained from cancer cells was examined using Transwell
inserts (Costar, Inc., NY, USA) [11]. In both assays,
endothelial cell exposure to CM lasted 24 h.
In some experiments, endothelial cell activity was
assessed upon their exposure to CM from cancer cells
modified by CM from senescent HPMCs pre-incubated
with antibodies against PAI-1 (20 lg/ml), u-PA (100
lg/ml), TGF-b1 (400 ng/ml), IL-6 (200 ng/ml), CXCL1
(10 lg/ml), CXCL8 (20 lg/ml), VEGF (5 lg/ml), sICAM-
1 (25 lg/ml), and TSP-1 (5 lg/ml), or with appropriate
control antibodies for 4 h with mixing. In other experi-
ments, endothelial cell proliferation and migration were
tested in the presence of CM from cancer cells pre-incu-
bated with specific neutralizing antibodies against CXCL1
(10 lg/ml), CXCL8 (20 lg/ml), HGF (10 lg/ml), and
VEGF (5 lg/ml), or with appropriate isotype-matched
control antibodies for 4 h with mixing. Some experiments
included the examination of endothelial cell behavior upon
the cells’ exposure to CM from cancer cells pre-incubated
with exogenous recombinant human IL-6 (5 ng/ml) and
TGF-b1 (1 ng/ml).
Animal studies
Experiments were performed on 6-week-old, immuno-
compromised Scid mice weighing 20–24 g (CB17/I cr-
Prkdc/I crI coCrl; Charles River, Wilmington, MA, USA).
The animals were housed (5/cage) in filter top cages
equipped with HEPA filters (Tecniplast, Buguggiate, Italy).
The room climate was maintained at a temperature of
22 ± 3 C, 40–65 % relative humidity, with 10 air changes
per hour. A commercial diet (ISO 9001 certified laboratory
feed, total pathogen free, Altromin, Germany) and drinking
water supplemented with amoxicillin at 2 g/1 liter (Taro-
mentin, Polfa, Poland) were available ad libitum. After a
passage of ovarian cancer cells and HPMCs, the animals
were injected i.p. with the cancer cells (A2780, OVCAR-3,
SKOV-3) alone or in combination with young or senescent
HPMCs in 100 ll of sterile PBS. The ratio of implanted
cancer cells to HPMCs was 1:1 (4 9 106 cells per animal
in total). The health status of the animals, including the
progression of intraperitoneal tumors, was inspected every
2 days. When the disease produced visible symptoms of
cachexia (after 21 days of the experiment), the animals
were sacrificed by i.m. injection of ketamine (30–35 mg/
kg) with xylazine (40–90 mg/kg). All procedures were
performed in compliance with EU Directive 2010/63/EU
and were approved by an institutional ethics committee.
After euthanasia, the peritoneal cavity of the experi-
mental animals was inspected by two qualified pathomor-
phologists and one oncologist. All tumors that had
developed in the peritoneum were excised, counted, mea-
sured and photographed. Afterwards, the tumors were fixed
in 4 % paraformaldehyde, dehydrated in alcohol series,
embedded in paraffin and cut into 4 lm sections in a
microtome. In order to identify the cancerous tissue, stan-
dard H ? E staining was performed. The tumor burden
was quantified according to the lesions’ count (as the total
tumor number) and to the calculation of total tumor volume
(using the formula: 0.5 9 width2 9 length [12]).
Tumor vascularization measurements
Tumor vascularization was examined according to
immunohistochemical detection of endothelial cell mark-
ers, i.e. CD31 and CD34 [13]. In brief, the specimens were
incubated with an antibody against CD31 (Leica Biosys-
tems, Buffalo Grove, IL) and against CD34 (Santa Cruz
Biotechnology, Santa Cruz, CA), both diluted in a ratio of
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1:25. Planimetric analysis of the brown-stained area
reflecting the presence of CD31/CD34-positive cells was
conducted using ImageJ 1.47v (Wayne Rasband, National
Institute of Health, USA). Six to eight 9 100 fields cov-
ering almost the whole of each of the six sections per group
were examined. The results were expressed as a percentage
(%), and the whole area of a specimen was treated as
100 %.
Transcription factor analysis
Activation of hypoxia-inducible factor-1 alpha (HIF-1a),
nuclear factor kappaB p50 subunit (NF-jB/p50) and acti-
vating protein-1 c-Jun subunit (AP-1/c-Jun) was examined
using TransAM kits (Active Motif, Carlsbad, CA), as per
manufacturer’s instructions. In some experiments the can-
cer cells were pre-treated (for 2 h) with Bay 87-2243
(2 nM), MG-132 (10 lM) or 3-AB (1 mM), which are
specific inhibitors of HIF-1a, NF-jB, and AP-1, respec-
tively, and then the CM generated by these cells was
applied to HUVECs in order to assess their proliferation
and migration. In other experiments the activation of the
transcription factors was tested in a dose–response
(0–10 ng/ml) and time-course (0–72 h) regimen upon
cancer cell exposure to exogenous recombinant forms of
IL-6 and TGF-b1, or in the presence of CM from senescent
HPMCs pre-incubated with neutralizing antibodies against
IL-6 (200 ng/ml) and TGF-b1 (400 ng/ml) or appropriate
isotype-matched controls.
Statistics
Statistical analysis was performed using GraphPad
PrismTM 5.00 software (GraphPad Software, San Diego,
USA). The means were compared with the Wilcoxon and
Mann–Whitney tests. Correlations were analyzed using the
Spearman test. Results were expressed as means ± SD.
Differences with a P value \0.05 were considered to be
statistically significant.
Results and discussion
It has recently been found that senescent cells, includ-
ing fibroblasts and mesothelial cells (HPMCs), secrete
increased amounts of agents to the environment that
stimulate angiogenic activity of the vascular endothelium
[7, 14]. Taking into account the fact that senescent cells
have been recognized to promote the progression of mul-
tiple types of cancers both in vitro and in vivo [15–17], the
pro-angiogenic capabilities of these cells seem to be of
special clinical significance.
In this report we verified our original hypothesis that
senescent HPMCs may contribute to increased aggres-
siveness of ovarian cancer by increasing the pro-angio-
genic capabilities of ovarian cancer cells. To this end, three
representative lines of ovarian cancer cells, namely A2780,
OVCAR-3, and SKOV-3 [18], were subjected to condi-
tioned medium (CM) generated by young and senescent
HPMCs, and then the secretion of six arbitrarily selected
angiogenic agents, i.e. CCL2, CXCL1, CXCL8, HGF, IL-
6, and VEGF [19, 20], by these cells was analyzed. The
experiments depicted in Fig. 1 show that the senescent
HPMCs were, indeed, capable of up-regulating the release
of certain angiogenesis mediators by the cancer cells, albeit
the pattern of this induction appeared to be specific for a
given cell line; A2780 cells appeared to produce increased
amounts of HGF and VEGF, OVCAR-3 cells increased the
amounts of CXCL1 and CXCL8, while the SKOV-3 cells
increased the amounts of CXCL1, CXCL8, and VEGF. It is
likely that these diversified responses may reflect, at least
partly, molecular differences among the investigated cell
lines which, though of similar origin, appeared to differ at
the genomic level [18].
Having established that senescent HPMCs increase the
production of certain pro-angiogenic agents by ovarian
cancer cells, primary cultures of endothelial cells
(HUVECs) were subjected in parallel to CM obtained from
cancer cells that had been pre-incubated with autologous
CM and to CM generated by cancer cells modified by
HPMCs. An analysis of angiogenic endothelial cell
behavior showed that either the proliferation or migration
of these cells was markedly improved when the cancer
cells were subjected to the activity of senescent HPMCs
(Fig. 2a–c). The same enhancement of endothelial cell
motility was observed when HUVECs were exposed to CM
produced by cancer cells co-cultured with senescent
HPMCs (Fig. 2d–f). Interestingly, markedly increased
proliferation and migration of the vascular endothelium
was also recorded when the cells were exposed to CM from
cancer cells undergoing pre-treatment with C generated by
young cells established from aged ([65 years old) donors
(vs. cells from patients\30 years old) (Fig. 3). The simi-
larity of the results as depicted in Figs. 2 and 3 confirms
our earlier suggestions that HPMCs isolated from aged
individuals may consist of a considerable fraction of
replicatively senescent cells which have the ability to
impose some phenotypical features of senescence on the
whole culture [21, 22]. Such a conclusion is in line with the
observations of other authors who found that senescent
fibroblasts modify the general characteristics of a culture
when they constitute even only 10 % of the whole popu-
lation [16].
Last but not least, the results obtained in these experi-
ments confirmed that the mediators released by the cancer
18 Clin Exp Metastasis (2016) 33:15–27
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cells upon their modification by senescent HPMCs were
biologically active. This conclusion stems from the
observation that the angiogenic behavior of endothelial
cells was significantly reduced when a CM generated by a
given cancer cell line was pre-incubated with specific
neutralizing antibodies directed against previously identi-
fied cell-specific pro-angiogenic stimuli (Table 1).
The reinforced angiogenic potential of endothelial cells,
initiated by senescent HPMCs and executed by the
malignant cells, appeared to be valid also in in vivo
Fig. 1 Effect of conditioned medium (CM) from young and senes-
cent HPMCs on the secretion of angiogenesis mediators by A2780
(a), OVCAR-3 (b), and SKOV-3 (c) ovarian cancer cells. The
asterisks indicate a significant difference as compared with cells
exposed to the CM from young HPMCs. Hashes indicate a significant
difference as compared with cells exposed to autologous CM from
intact cancer cells. Experiments were performed with HPMCs from 8
different donors (samples were not pooled). The cancer cells were
used in triplicates
Fig. 2 Modulatory effect of HPMCs on ovarian cancer cell-depen-
dent angiogenic activity of endothelial cells in vitro. Both prolifer-
ation (PROL) and migration (MIGR) of endothelial cells (HUVECs)
were examined in response to their exposure (24 h) to CM harvested
from A2780 (a), OVCAR-3 (b), and SKOV-3 (c) ovarian cancer cells
which were pre-incubated with CM from young and senescent
HPMCs, or in response to exposure to CM generated by A2780 (d),
OVCAR-3 (e), and SKOV-3 cells (f) co-cultured with young and
senescent HPMCs. Single asterisks indicate a significant difference as
compared with cells subjected to CM from cancer cells pre-incubated
with CM from young HPMCs. Double asterisks indicate a significant
difference as compared with cells subjected to CM from cancer cells
pre-incubated with autologous CM (treated as 100 %). Experiments
were performed with HPMCs from 8 different donors whose age
ranged from 34 to 38 years old (samples were not pooled). Ovarian
cancer cells were used in hexaplicates. Endothelial cells were used in
duplicates
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conditions. The experiments showed that xenografts which
had developed in the mouse peritoneum upon i.p. injection
of ovarian cancer cells together with senescent HPMCs
were significantly larger and their number was higher as
compared with lesions fueled by young HPMCs (Fig. 4). It
is likely that this effect was associated with an increased
density of the microvessels, as evidenced according to
immunohistochemistry against the endothelial cell markers
CD31 and CD34 [13] (Fig. 5). These findings are in
accordance with previous studies on mice which proved
that effective angiogenesis is critical for successful devel-
opment of ovarian tumors [23]. They are also in agreement
with a report by Liu and Hornsby, who showed that breast
cancer cells create solid tumors more effectively when they
are cotransplanted in mice in combination with senescent
fibroblasts [12]. Interestingly, also in this case the primary
mechanism of the pro-cancerous activity of senescent cells
was related to their impact on tumor vasculature, in
particular a metalloproteinase-related increase in perme-
ability, which led to increased inflow of cancer-promoting
stimuli [12]. Last but not least, it is worth noting that
increased tumor growth in animals co-injected with cancer
cells with young HPMCs in comparison with those in
which only ovarian cancer cells were implanted (Fig. 4)
confirms our earlier hypothesis that the mesothelial cells
themselves play an important cancer-promoting role in the
early steps of intraperitoneal ovarian cancer metastasis [4].
At the same time, the lack of an analogical effect with
respect to tumor vascularization (Fig. 5) may indicate that
the stimulatory activity of young mesothelial cells towards
ovarian cancer may be related to improved cancer cell
adhesion and/or proliferation rather than to the strength-
ened angiogenic activity of endothelial cells.
Mechanistically, increased secretion of angiogenic fac-
tors by cancer cells subjected to senescent HPMCs has
been found to be driven by two cytokines, IL-6 and TGF-
Fig. 3 Modulatory effect of HPMCs on ovarian cancer cell-depen-
dent angiogenic activity of endothelial cells in vitro. Both prolifer-
ation (PROL) and migration (MIGR) of endothelial cells (HUVECs)
were examined in response to the cells’ exposure (24 h) to CM
harvested from A2780 (a), OVCAR-3 (b), and SKOV-3 (c) ovarian
cancer cells which were pre-incubated with CM from early-passage
HPMCs isolated from young (\30 years old, n = 6) and old
([65 years old, n = 6) individuals. Single asterisks indicate a
significant difference as compared with cells subjected to CM from
cancer cells pre-incubated with CM from young donors. Double
asterisks indicate a significant difference as compared with cells
subjected to CM from cancer cells pre-incubated with autologous CM
(treated as 100 %). Experiments were performed with HPMCs from
12 different donors whose age ranged from 19 to 85 years old
(samples were not pooled). Ovarian cancer cells were used in
hexaplicates. Endothelial cells were used in duplicates
Table 1 Proliferation and
migration of endothelial cells in
response to CM from ovarian





Neutralized mediator HUVEC proliferation HUVEC migration
A2780 OVCAR-3 SKOV-3 A2780 OVCAR-3 SKOV-3
CXCL1 98 ± 6 77 ± 5* 56 ± 1* 100 ± 3 95 ± 8 67 ± 7*
CXCL8 104 ± 8 88 ± 2* 89 ± 3* 104 ± 4 44 ± 2* 41 ± 3*
HGF 55 ± 6* 103 ± 7 98 ± 4 78 ± 3* 102 ± 3 99 ± 2
VEGF 65 ± 4* 102 ± 5 45 ± 2* 66 ± 1* 101 ± 4 45 ± 4*
The values are expressed as a percentage of endothelial cell proliferation/migration upon treatment with an
intact CM from cancer cells pre-incubated with CM from senescent HPMCs (considered as 100 %). The
concentrations of antibodies used here are provided in the ‘‘Materials and methods’’ section. The results
derive from experiments performed with CM generated by HPMCs from 8 different donors. Cancer cells
and endothelial cells were used in hexaplicates. The asterisks indicate a significant decrease in endothelial
cell proliferation/migration
20 Clin Exp Metastasis (2016) 33:15–27
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b1, which have often been postulated as being involved in
tumor neovascularization and in metastasis development
efficiency [24]. Experiments have shown that among all of
the soluble mediators released at an increased level by
senescent HPMCs [25], only the neutralization of IL-6 and
TGF-b1 in the CM from senescent cells led to a significant
reduction of the pro-angiogenic activity of the cancer cells.
When antibodies against the rest of the agents hyper-
secreted by senescent HPMCs, including CXCL1, CXCL8,
ICAM-1, PAI-1, uPA, TSP-1, and VEGF, were used, both
the proliferation and migration of the endothelial cells
remained unchanged (Table 2). Moreover, the production
of previously identified, cancer cell line-specific pro-
angiogenic mediators (HGF, VEGF, CXCL1, and CXCL8)
was markedly decreased when the CM generated by
senescent HPMCs was pre-incubated with antibodies neu-
tralizing IL-6 and TGF-b1 (Table 3).
In order to provide definitive evidence that the pro-an-
giogenic activity of mesothelium-derived IL-6 and TGF-b1
proceeds via stimulation of the release of specific angio-
genic agents by ovarian cancer cells, we quantified both of
these cytokines in the CM from young and senescent
HPMCs and then correlated their level in the latter with the
concentration of HGF, VEGF, CXCL1, and CXCL8 in the
CM from A2780, OVCAR-3, and SKOV-3 cells. These
analyses showed that, indeed, the senescence of primary
Fig. 4 Development of tumors in the mouse peritoneal cavity upon
injection of ovarian cancer cells with young and senescent HPMCs.
Ovarian cancer cells (A2780, OVCAR-3, SKOV-3) alone or mixtures
of ovarian cancer cells with respective HPMCs (1:1 ratio, 4 9 106
cells in total) were injected intraperitoneally and the formation of
xenografts was monitored for 21 days. The tumor burden was
quantified according to the total tumor volume (a) and the total
tumor number (b). Representative pictures showing tumors (marked
with arrows) that developed upon the co-transplantation of A2780
cells together with young and senescent HPMCs (c). The single
asterisks indicate a significant difference as compared with the
xenografts that developed in the presence of young HPMCs. The
double asterisks indicate a significant difference as compared with the
xenografts that developed in the absence of HPMCs. Experiments
were performed with HPMCs from 6 different donors and with 6 pairs
of animals (each pair received cancer cells and young or senescent
HPMCs from the same donor)
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HPMCs used in this study was associated with a significant
increase in IL-6 and TGF-b1 secretion (Fig. 6), and that the
higher their level in the CM from senescent cells was, the
higher the production of angiogenesis mediators by cancer
cells undergoing exposure to mesothelium-derived CM was
(Table 4). The latter is in agreement with our further
observations that both the proliferation and migration of
endothelial cells were markedly intensified when the cells
were exposed to CM from ovarian cancer cells, pre-incu-
bated with exogenous recombinant forms of IL-6 and TGF-
b1, and used at concentrations corresponding to their level
in the CM from senescent HPMCs (Fig. 7).
When it comes to the signaling pathways initiated in the
cancer cells upon their exposure to HPMC-derived CM
(read: IL-6 and TGF-b1) and underlying their sharpened
pro-angiogenic potential, the activation of three transcrip-
tion factors involved in angiogenesis, i.e. HIF-1a, NF-
jB/p50, and AP-1/c-Jun [19, 26], was examined. The
experiments showed that senescent HPMCs elicited the
pro-angiogenic cancer cell response by increasing the
transcriptional activity of HIF-1a, NF-jB/p50 (in A2780
and SKOV-3 cells), and AP-/c-Jun (in OVCAR-3 cells),
which was revealed by an analysis of the nuclear binding
efficacy of these factors (Fig. 8). This was confirmed when
Fig. 5 Magnitude of angiogenesis in tumors that developed upon i.p.
injection of ovarian cancer cells alone or in combination with young
and senescent HPMCs. The results derive from experiments as shown
and described in Fig. 4. Representative images showing the results of
immunostaining for markers of the vascular endothelium, CD31
(a) and CD34 (c). CD31/CD34-positive cells display brown mem-
brane and/or cytoplasm staining (some examples are marked with
arrows). Quantification of the brown-stained area reflecting the
presence of CD31- (b) and CD34-positive cells (d). The results are
expressed as a percentage, and the whole area of a specimen is
considered as 100 %. The single asterisks indicate a significant
difference as compared with the xenografts that developed in the
presence of young HPMCs. The double asterisks indicate a significant
difference as compared with the xenografts that developed in the
absence of HPMCs. Experiments were performed with HPMCs from
6 different donors and with 6 pairs of animals (each pair received
cancer cells and young or senescent HPMCs from the same donor)
22 Clin Exp Metastasis (2016) 33:15–27
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Table 2 Proliferation and
migration of endothelial cells in
response to CM from ovarian
cancer cells pre-incubated with
CM from senescent HPMCs in
which individual proteins were
neutralized
Neutralized mediator HUVEC proliferation HUVEC migration
A2780 OVCAR-3 SKOV-3 A2780 OVCAR-3 SKOV-3
CXCL1 104 ± 5 111 ± 3 124 ± 12 105 ± 6 89 ± 11 89 ± 21
CXCL8 92 ± 6 92 ± 8 100 ± 4 103 ± 5 101 ± 8 102 ± 6
IL-6 72 ± 3* 64 ± 5* 68 ± 2* 64 ± 6* 81 ± 4* 78 ± 2*
PAI-1 113 ± 22 115 ± 21 104 ± 5 101 ± 1 105 ± 9 106 ± 6
u-PA 92 ± 11 95 ± 7 99 ± 1 98 ± 12 95 ± 5 101 ± 3
sICAM-1 107 ± 2 110 ± 8 96 ± 16 102 ± 11 103 ± 4 100 ± 8
TGF-b1 84 ± 5* 81 ± 2* 87 ± 4* 84 ± 2* 88 ± 1* 103 ± 8
TSP-1 106 ± 12 102 ± 5 102 ± 3 101 ± 1 112 ± 5 102 ± 7
VEGF 96 ± 3 91 ± 8 106 ± 8 98 ± 2 101 ± 1 92 ± 9
The values are expressed as a percentage of endothelial cell proliferation/migration upon incubation with
CM from cancer cells pre-treated with an intact CM from senescent HPMCs (considered as 100 %). Please
note that the neutralization of IL-6 and TGF-b1 decreased both the proliferation and migration of
endothelial cells to a level characterizing their behavior upon exposure to CM generated by cancer cells
pre-incubated with an autologous CM. The concentrations of all antibodies used here are provided in the
‘‘Materials and methods’’ section. The results derive from experiments performed with CM produced by
HPMCs from 8 different donors. Cancer cells and endothelial cells were used in hexaplicates. The asterisks
indicate a significant decrease in endothelial cell proliferation/migration
Table 3 Secretion of pro-angiogenic agents by ovarian cancer cells in response to a conditioned medium generated by senescent HPMCs upon
its pre-incubation with antibodies neutralizing IL-6 and TGF-b1
Neutralized mediator A2780 OVCAR-3 SKOV-3
HGF VEGF CXCL1 CXCL8 CXCL1 CXCL8 VEGF
IL-6 88 ± 3* 72 ± 4* 91 ± 2* 64 ± 3* 81 ± 2* 66 ± 3* 72 ± 1*
TGF-b1 76 ± 3* 82 ± 1* 78 ± 2* 76 ± 2* 80 ± 5* 71 ± 2* 67 ± 8*
Samples of CM from senescent HPMCs were pre-incubated with antibodies against IL-6 (200 ng/ml) and TGF-b1 (400 ng/ml) for 24 h.
Afterwards, the media were added to ovarian cancer cells for 24 h. After incubation, the media were removed and the cells were exposed to fresh
serum-free media for 24 h to generate autologous CM in which the angiogenic agent level was quantified. The values are expressed as a
percentage of the control cells (cancer cells exposed to CM from senescent HPMCs without IL-6/TGF-b1 neutralization are considered as
100 %). The results derive from experiments performed with CM produced by HPMCs from 6 different donors. Cancer cells were used in
hexaplicates. The asterisks indicate a significant difference as compared with the control group
Fig. 6 Changes in IL-6 (a) and
TGF-b1 (b) production during
senescence of primary HPMCs.
The concentration of both
cytokines was quantified in CM
obtained from early-passage and
senescent cells. Asterisks
indicate a significant difference
as compared with CM from
young HPMCs. Experiments
were performed with HPMCs
from 22 different donors
(samples were not pooled)
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Table 4 Correlation between
the concentration of IL-6 and
TGF-b1 in conditioned medium
from senescent HPMCs and the
concentration of HGF, VEGF,
CXCL1, and CXCL8 in
media generated by A2780,
OVCAR-3, and SKOV-3 cells
Senescent HPMCs A2780 OVCAR-3 SKOV-3





























Ovarian cancer cells were exposed to CM obtained from senescent HPMCs for 24 h. Afterwards, the media
were removed, the cells were washed and then subjected to serum-free medium (for 24 h) to generate
autologous CM. Concentrations of IL-6 and TGF-b1 in the CM from senescent HPMCs were correlated
with concentrations of HGF, VEGF, CXCL1, and CXCL8 quantified in cancer cell-derived CM using the
Spearman test. The results derive from experiments performed with CM produced by HPMCs from 22
different donors
Fig. 7 Effect of exogenous, recombinant forms of human IL-6 and
TGF-b1 on ovarian cancer cell-dependent angiogenic reactions of
endothelial cells. Both proliferation (PROL) and migration (MIGR) of
endothelial cells (HUVECs) were examined in response to CM from
A2780 (a, d), OVCAR-3 (b, e), and SKOV-3 cells (c, f) which were
pre-incubated with recombinant human (rh) IL-6 (5 ng/ml) and
TGF-b1 (1 ng/ml). Asterisks indicate a significant difference as
compared with endothelial cells subjected to CM from cancer cells
not exposed to rhIL-6 or rhTGF-b1 (treated as 100 %). Experiments
were performed with CM obtained from 6 separate cultures of ovarian
cancer cells (for each cell line). Endothelial cells were used in
duplicates
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Fig. 8 Activation of transcription factors involved in angiogenic
endothelial cell reactions in ovarian cancer cells in response to
senescence of HPMCs. Ovarian cancer cell lines A2780 (a), OVCAR-
3 (b), and SKOV-3 (c) were subjected to conditioned medium from
young and senescent HPMCs (24 h) and then the activation of HIF-
1a, NF-jB, and AP-1 in the cancer cells was examined. Single
asterisks indicate a significant difference as compared with cells
exposed to CM from young HPMCs. Double asterisks indicate a
significant difference as compared with cells subjected to autologous
CM (treated as 100 %). Experiments were performed with HPMCs
from 8 different donors (samples were not pooled). Ovarian cancer
cells were used in hexaplicates
Fig. 9 Transcriptional regulation of senescent HPMC-dependent
stimulation of the pro-angiogenic activity of ovarian cancer cells. In
the experiments, both the proliferation (upper panel) and migration
(bottom panel) of endothelial cells (HUVECs) were evaluated upon
their exposure (24 h) to CM from cancer cells (a, d A2780;
b, e OVCAR-3; c, f SKOV-3), whose incubation with HPMC-
derived CM was preceded by pre-treatment with Bay 87-2243, MG-
132, and 3-AB which inhibit HIF-1a, NF-jB, and AP-1, respectively.
The concentrations of inhibitors used here are provided in the see
‘‘Materials and methods’’ section. Asterisks indicate a significant
difference as compared with cells exposed to CM from young or
senescent HPMCs not treated with the transcription factor inhibitors.
Experiments were performed with HPMCs from 8 different donors
(samples were not pooled). Ovarian cancer cells were used in
hexaplicates
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both the proliferation and migration of endothelial cells
were studied upon cancer cell pre-incubation with tran-
scription factor-specific inhibitors. Interestingly, when it
comes to the effect of young HPMCs on cancer cell-de-
pendent stimulation of angiogenesis, this activity was
related exclusively to HIF-1a (Fig. 9). Further research
showed that recombinant forms of both IL-6 and TGF-b1
are truly able to increase the nuclear binding of the studied
transcription factors in both a dose- and time-dependent
manner (Fig. 10), while neutralization of these proteins
using specific antibodies in CM from senescent HPMCs
significantly reduced their activation (not shown). These
findings pointing to the interplay between IL-6 and TGF-b1
and pro-angiogenic transcription factor activity are in
agreement with observations that have been made by other
authors (e.g. [27, 28] ).
Taken together, our findings indicate that senescent
HPMCs promote angiogenesis not only directly, i.e. by
stimulating endothelial cell motility [7], but also indirectly,
i.e. by modulating the secretory profile of the ovarian
cancer cells. This phenomenon may constitute a new
mechanism by which senescent HPMCs, known to accu-
mulate in the peritoneum with age [8], may create a
metastatic niche which allows ovarian cancer cells to
acquire a more aggressive phenotype and thereby to more
effectively colonize the peritoneal cavity.
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